Thymosin Beta-4 (TB-4): Research Overview

Thymosin beta-4 (Tβ4) is a 43-amino-acid peptide originally isolated from bovine thymus tissue and now known to be expressed in virtually every nucleated cell type in the human body. It holds a central role in actin dynamics — sequestering G-actin monomers to regulate the cytoskeletal changes that underlie cell migration, wound closure, and tissue repair. Interest from pharmaceutical researchers grew sharply after preclinical work demonstrated cardiac-protective effects following myocardial infarction, corneal healing, and hair follicle activation. Two phase 1 human safety studies have been completed with IV-administered synthetic Tβ4, making it one of the few research peptides backed by published human pharmacokinetic data.

What is Thymosin Beta-4?

Thymosin beta-4 belongs to the beta-thymosin family of small actin-binding polypeptides. The full-length molecule spans 43 residues with a molecular weight of approximately 4.9 kDa. It is encoded by the TMSB4X gene and, unlike many peptide hormones, it does not bind a single classical transmembrane receptor; instead its activity depends on direct protein-protein interactions with G-actin and downstream signaling partners. Regulatory status worldwide classifies synthetic Tβ4 as a research compound: it is not approved by the FDA, EMA, or any other major drug authority for human therapeutic use. Research-chemical vendors typically supply it as a lyophilized powder in 2 mg or 10 mg vials.

Mechanism of Action

The dominant molecular function of Tβ4 is sequestration of monomeric (G-) actin. The peptide harbors a conserved LKKTET motif spanning residues 17–22 that forms the primary actin-binding interface. By holding free G-actin in a sequestered pool, Tβ4 modulates the equilibrium between the monomeric and filamentous (F-actin) forms of actin, effectively regulating the rate of actin polymerization at the leading edge of migrating cells. This mechanism is required for lamellipodia formation and directional cell migration — processes central to wound healing and tissue remodeling.

Beyond actin sequestration, Tβ4 upregulates integrin-linked kinase (ILK), which in turn activates the PI3K/Akt survival pathway. In cardiac models, elevated Akt activity after Tβ4 administration was associated with reduced cardiomyocyte apoptosis and enhanced angiogenesis following coronary artery ligation. Tβ4 also mobilizes epicardial progenitor cells and promotes endothelial migration, both of which contribute to the vascular remodeling observed in preclinical myocardial injury experiments.

What the Research Shows

Preclinical work in rodent myocardial infarction models demonstrated that Tβ4 treatment after coronary artery ligation improved ejection fraction, reduced scar size, and promoted angiogenesis compared with vehicle controls (Bock-Marquette et al., 2004; Sopko et al., 2011). A 2007 study published in Nature (PMID 17600280) showed that Tβ4 is cardioprotective after MI by activating epicardial progenitors — an effect dependent on ILK upregulation.

In human studies, a randomized, placebo-controlled phase 1A/1B trial published in the Annals of the New York Academy of Sciences (Goldstein et al., 2010; PMID 20536472) enrolled 40 healthy volunteers who received single intravenous doses of 42, 140, 420, or 1260 mg. No dose-limiting toxicities or serious adverse events were reported. A separate phase 1 study of recombinant human Tβ4 in healthy Chinese volunteers (Wang et al., 2021; PMID 34346165) evaluated both single and multiple subcutaneous doses. Both studies established a safety and tolerability profile but did not evaluate efficacy endpoints in patients. A phase 1B follow-up trial in healthy volunteers (NCT04555850) appears on ClinicalTrials.gov but results have not been fully published as of this writing.

Pharmacokinetics

The phase 1A study reported a mean elimination half-life of approximately 0.5–1.5 hours after intravenous administration, with plasma concentrations declining rapidly in a biphasic pattern. Volume of distribution was low, consistent with primarily extracellular distribution. Because the published human studies used intravenous delivery exclusively (with the exception of the Wang et al. subcutaneous cohort), human PK data for the subcutaneous route used by research vendors remain limited. The recombinant SC study reported that peak plasma concentrations were achieved within 1–3 hours post-injection. Tβ4 is thought to be cleared by proteolytic degradation, with no major active metabolites identified.

Common Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

The only published human dose-escalation data for Tβ4 come from intravenous administration. The phase 1A/1B trial (Goldstein et al., 2010; PMID 20536472) used IV single doses of 42–1260 mg in healthy volunteers. The recombinant SC study (Wang et al., 2021; PMID 34346165) investigated substantially lower dose levels via subcutaneous injection. Literature reports single and repeated intravenous dosing in phase 1 safety studies; subcutaneous routes were investigated in separate cohorts. It is important to note that the IV dose range (42–1260 mg) is not directly comparable to SC administration and does not represent a validated subcutaneous dose range.

Storage

Lyophilized (powder) Tβ4 should be stored at −20 °C in a dry, light-protected environment. Once reconstituted with bacteriostatic water, the solution is typically stable for up to 28 days when kept at 2–8 °C and protected from light. Freeze-thaw cycling degrades peptide integrity; aliquoting before initial freeze is standard practice in research settings.

What Thymosin Beta-4 Is NOT

Thymosin beta-4 (TB-4) is frequently confused with TB-500, which is a synthetic fragment corresponding to residues 17–23 of the full-length Tβ4 sequence — the minimal actin-binding LKKTET motif. TB-500 is not the same molecule as TB-4: it is substantially shorter (889 Da vs. ~4.9 kDa), lacks the N-terminal and C-terminal domains of the full peptide, and has a distinct pharmacokinetic profile. The preclinical cardiac-repair and corneal-healing studies cited in the literature used full-length Tβ4, not the TB-500 fragment. Additionally, Tβ4 is entirely unrelated to Thymosin alpha-1 (Thymalfasin), a different thymic peptide used clinically in some countries as an immunostimulant.

References

Citations for this guide are listed below. All PubMed links resolve to the NCBI abstract page for the referenced article. ClinicalTrials.gov links resolve to the registered study record.